2-Chloro-4-fluorotoluene

We are 2-Chloro-4-fluorotoluene CAS:452-73-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 2-Chloro-4-fluorotoluene
Other Name: 2-Chloro-4-fluoro-1-methylbenzene
CAS No: 452-73-3
MF: C7H6ClF
MW: 144.57400
Density: 1.2±0.1 g/cm3
Boiling point: 155.2±20.0 °C at 760 mmHg
Flash point: 50.0±0.0 °C
Refractive index: 1.502
Vapor Pressure: 3.9±0.3 mmHg at 25°C
UN Number: UN1993
UN Proper Shipping Name: FLAMMABLE LIQUID, N.O.S.
Transport hazard class: 3
Packing group: III
 
Specification
Appearance: Colorless transparent liquid
Purity: ≥98%
Water: ≤0.5%
 
Application: Organic intermediates, pharmaceutical intermediates, agrochemical intermediates.
Package: 25kg/drum, packed in plastic drum or plastic coated iron drum.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

2-Chloro-4-fluorotoluene


Related News: Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.2-bromo-2-metilpropionato de metilo CAS:23426-63-3 Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.179688-26-7 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-(4,6-Diphenyl-1,3,5-triazine-2-yl)-5-[(hexyl)oxy]phenol CAS:147315-50-2 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.The mode of cooperation between domestic API companies and large international companies can lower the export threshold.

Related Products
Product Name
thymidine View Details
5-Fluoro-2-methylbenzaldehyde View Details
perfluorohexane Cas:355-42-0 View Details
(3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane manufacturer 2-Hydroxy-4-methoxybenzaldehyde manufacturer 4-BROMO-3-CHLOROBENZOIC ACID manufacturer 5-Bromo-2-fluorophenol manufacturer 3-Formyl-6-isopropylchromone manufacturer